CN105456284B - A kind of drug for treating cough - Google Patents
A kind of drug for treating cough Download PDFInfo
- Publication number
- CN105456284B CN105456284B CN201610001603.2A CN201610001603A CN105456284B CN 105456284 B CN105456284 B CN 105456284B CN 201610001603 A CN201610001603 A CN 201610001603A CN 105456284 B CN105456284 B CN 105456284B
- Authority
- CN
- China
- Prior art keywords
- cough
- pharmaceutical composition
- lysine
- lamp
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010011224 Cough Diseases 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims description 17
- 229940079593 drug Drugs 0.000 title claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000004472 Lysine Substances 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 239000000470 constituent Substances 0.000 claims abstract description 5
- 241000132521 Erigeron Species 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- -1 cataplasm Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 7
- 230000000954 anitussive effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229940124584 antitussives Drugs 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- 241000605372 Fritillaria Species 0.000 description 2
- 241001287809 Nierembergia Species 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- YWJXCIXBAKGUKZ-HJJNZUOJSA-N Bergenin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H]2C3=C(O)C(OC)=C(O)C=C3C(=O)O[C@@H]21 YWJXCIXBAKGUKZ-HJJNZUOJSA-N 0.000 description 1
- XULPLJSODQQHPH-UHFFFAOYSA-N Bergenin Natural products OCC1OC2C(OC(=O)c3cc(O)c(CO)c(O)c23)C(O)C1O XULPLJSODQQHPH-UHFFFAOYSA-N 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241001092500 Photinia x fraseri Species 0.000 description 1
- 240000002924 Platycladus orientalis Species 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241001671204 Stemona Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of for treating the pharmaceutical composition of cough, wherein active constituent includes lamp-dish flower acetic and lysine, and the two weight ratio is 5 15:3‑10.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions for treating cough.
Background technology
Due to the increasingly variation of environment for human survival, as the respiratory system caused by mankind itself's sensibility and environmental pollution
The incidence of disease constantly rises, wherein cough is one of common sympton of respiratory disease.The main syndromes of lung system illness
One of be exactly to cough.Throughout history, ancient Chinese medicine doctor have different opinion for cough.《The Yellow Emperor's Canon of Internal Medicine》It is proposed that " vital organs of the human body are all
Make us cough, non-only lung " demonstration ".《Jing Yue's complete work》Again opinion " one card of cough, be surreptitiously seen in family set forth one's views it is big numerous, all must not its will,
It is descendant is caused to face card Mo Zhisuo from so controlling rare effect " more.Zhang Jingyue will cough card by being divided into diseases caused by external factors, two class of internal injury.《Interchannel six
Book》In refer to " cold and heat eliminating dampness wind fire six gas, all make us cough " again.Cough is both disease and syndrome, and any age can fall ill, the winter
Spring is common.
Current clinically used antitussive is the compound preparation of chemicals and Chinese medicine mostly.Chemicals presses town
The cough mechanism of action can be divided into two class of central and peripheral antitussive drugs.Central antitussive, be mostly opiates and its
Derivative, such as codeine (methylmorphine).This kind of drug discovery is early, antibechic effect is also preferable, but with dependence, therefore at present
Clinically using less.Although it is developed on the basis of opiates structure-activity relationship is analyzed by changing structure or synthesis
The smaller maincenter antitussive of dependence such as dextromethorphan (right first morphine), but be also required to give fully its side effect on using
Attention.Peripheral antitussive drugs, such as coscopin, majority are also alkaloids medicament, and nausea, palpitaition, head can be generated when taking
It is dizzy to wait adverse reactions.And some Chinese medicines, such as fritillaria, Chinese ephedra, Radix Glycyrrhizae, purple perilla, cuckoo, the bark of ash, it has been proved to have good
Antitussive effect, these Chinese medicine majorities are to be applied to clinic, the monomer town developed from these Chinese medicines in the form of compound preparation
Cough medicine is very few, at present into only ephedrine, Bergenin etc. of clinical practice a few.CN102078558A is disclosed
A kind of pharmaceutical composition for treating cough, the weight proportion of wherein bulk pharmaceutical chemicals are as follows：30 parts of uncaria, 40 parts of Tabasheer, campanulaceae 1
0 part, 50 parts of fructus amomi, 50 parts of dried orange peel, 10 parts of Poria cocos, 50 parts of peppermint, 20 parts of Radix Glycyrrhizae, 7 parts of cow-bezoar.CN101991802A discloses one
Kind treats the Chinese medicine preparation of cold cough, contains 30 parts of honeysuckle, 30 parts of dried orange peel, 25 parts of oriental wormwood, 35 parts of the tuber of stemona, Radix Glycyrrhizae 30
Part, 25 parts of semen armeniacae amarae, 25 parts of the seed of Oriental arborvitae, 20 parts of fritillaria, 30 parts of campanulaceae, 20 parts of jujube, 15 parts of dry moxa leaf and suitable honey.
Invention content
The present invention provides it is a kind of for treat cough pharmaceutical composition, wherein active constituent include lamp-dish flower acetic and
Lysine.
In a specific embodiment, the present invention provides a kind of for treating the pharmaceutical composition of cough, wherein living
Property ingredient is made of lamp-dish flower acetic and lysine.
In a specific embodiment, the present invention provides a kind of for treating the pharmaceutical composition of cough, wherein lamp
The weight ratio of small cup flower B prime and lysine is 5-15:3-10.
In a specific embodiment, the present invention provides a kind of for treating the pharmaceutical composition of cough, wherein lamp
The weight ratio of small cup flower B prime and lysine is 12:7.
In a specific embodiment, the present invention provides a kind of for treating the pharmaceutical composition of cough, wherein also
Including the auxiliary material pharmaceutically received.
In a specific embodiment, the present invention provides the pharmaceutical compositions including lamp-dish flower acetic and lysine to exist
Prepare the purposes in the drug for treating cough.
Lamp-dish flower acetic is the flavonoids effective constituent extracted from the former grass of fleabane flower, is commercially available.
The extracting method of lamp-dish flower acetic has been recorded in CN101497637A.Known fleabane flower has treatment cardiovascular and cerebrovascular disease, glycosuria
Sick isoreactivity.
Lysine is one of essential amino acid, can promote human development, enhancing immune function, and be improved maincenter god
Effect through function of organization.The symptom for lacking lysine includes fatigue, weakness, Nausea and vomiting, dizziness etc..Known lysine can
Herpes labialis caused by for treating herpes simplex virus and herpes zoster.
Before the present invention, not it has been reported that lamp-dish flower acetic can be used for treatment to cough, also by lamp-dish flower acetic and bad
The report that propylhomoserin compatibility is coughed for treatment.Present invention applicant had been surprisingly found that lamp-dish flower acetic and lysine compatibility, for
Treatment cough has unexpected remarkable result, has synergistic effect especially with respect to single component.
Pharmaceutical composition of the present invention can prepare piece agent, capsule, injection, dripping pill, pellet, cataplasm, ointment,
The dosage forms such as suspension, dispersible tablet, effervescent tablet.
It is not bound to theory, pharmaceutical preparation of the present invention can use appropriate auxiliary material known to pharmaceutical field, using this
Preparation method known to field technology personnel is made.
Pharmaceutical composition of the present invention is unlimited for applicable object, can be used for mammal, the preferably mankind.Made
Dosage is determined according to conditions of patients and feature itself by medical matters practitioner.
Specific embodiment
Embodiment 1
Pharmaceutical composition active constituent：
Lamp-dish flower acetic：Lysine 5:3
It takes lamp-dish flower acetic 5g, lysine 3g, adds in starch dust 100g, with equal increments method mixing, with 80% second
Particle is made in alcohol, dry, whole grain, mixing, adds in talcum powder 4g, magnesium stearate 1.6g, tabletting is up to (1000).
Embodiment 2
Lamp-dish flower acetic：Lysine 15:10
It takes lamp-dish flower acetic 15g, lysine 10g, adds in starch dust 100g, with equal increments method mixing, with 80%
Particle is made in ethyl alcohol, dry, whole grain, mixing, adds in talcum powder 4g, magnesium stearate 1.6g, tabletting is up to (1000).
Embodiment 3
Lamp-dish flower acetic：Lysine 12:7
It takes lamp-dish flower acetic 12g, lysine 7g, adds in starch dust 100g, with equal increments method mixing, with 80% second
Particle is made in alcohol, dry, whole grain, mixing, adds in talcum powder 4g, magnesium stearate 1.6g, tabletting is up to (1000).
Pharmacology Bioexperiment
Experimental example 4：The antitussive effect of mouse cough model is caused to sulfur dioxide smog
The mouse of 18-22 g is randomly divided into 7 groups, model control group gives gavage physiological saline, and tested group is given gavage
Drug sample described in embodiment 1-3 and reference substance 1-3, successive administration 5 days.In 30 minutes after the last administration, mouse is put closed
In glass box, the smog induction for quantitatively spraying into sulfur burning generation causes cough, cough time in record mouse cough incubation period and 3 minutes
Number, experimental result are as shown in table 1.
1 drug sample of the present invention of table causes sulfur dioxide smog the antitussive effect of mouse cough（± S, n=15）
The results show that the lamp-dish flower acetic of doubling dose or lysine is used alone does not have antibechic effect substantially.Fleabane flower
The composition of B prime and lysine can effectively treat cough, wherein with 12:7 effect is best, compared to individually making
With lamp-dish flower acetic or lysine, there is synergistic therapeutic effect.The pharmaceutical composition of lamp-dish flower acetic and lysine even compares
Dextromethorphan hydrobromide（List antibechic commodity）With better antibechic effect.
5 clinical therapeutic efficacy of embodiment：
Criterion of therapeutical effect：Curative effect judges whether Main Basiss disappear for cough symptom.Medication 15 days for a course for the treatment of.It is specific to treat
The following three-level of effect point：Cure --- cough symptom all disappears；Improving --- cough symptom is substantially reduced；In vain --- medication 1
After a course for the treatment of, cough symptom has no to disappear.
Effect：With 3 drug therapy cough patients of the embodiment of the present invention 50,1 course for the treatment of is treated, wherein 46 are cured, it is good
Turn 4, cure rate 92.0%, effective percentage is 100%.
Model case：
Mr. Wang, female, 60 years old.In August, 2014 is gone to a doctor.Patient's readme, criminal's cough, which has ten, has a surplus.Symptom cough gas
It is short, viscous Huang of coughing up phlegm, pharyngalgia, micro- aversion to wind and cold.Tongue is thin white, red tip of tongue, superficial and rapid pulse.Using drug of the present invention, first take 10 days, symptom is bright
It is aobvious to improve, it subsequently takes 5 days, fully recovers.It visits within 2 months, no relapse.
Claims (6)
1. a kind of pharmaceutical composition, which is characterized in that its active constituent includes lamp-dish flower acetic and lysine, wherein fleabane flower second
The weight ratio of element and lysine is 5-15:3-10.
2. pharmaceutical composition as described in claim 1, which is characterized in that the wherein weight ratio of lamp-dish flower acetic and lysine
It is 12:7.
3. pharmaceutical composition as claimed in claim 1 or 2, which is characterized in that wherein further include the auxiliary material pharmaceutically received.
4. pharmaceutical composition as claimed in claim 1 or 2, which is characterized in that wherein pharmaceutical composition prepares piece agent, glue
Capsule, injection, dripping pill, pellet, cataplasm, ointment, suspension, dispersible tablet or effervescent tablet.
5. claim 1-4 any one of them pharmaceutical composition is as the drug for treatment cough.
6. purposes of the claim 1-4 any one of them pharmaceutical composition in the drug for treating cough is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610001603.2A CN105456284B (en) | 2016-01-05 | 2016-01-05 | A kind of drug for treating cough |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610001603.2A CN105456284B (en) | 2016-01-05 | 2016-01-05 | A kind of drug for treating cough |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105456284A CN105456284A (en) | 2016-04-06 |
| CN105456284B true CN105456284B (en) | 2018-06-15 |
Family
ID=55594749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610001603.2A Active CN105456284B (en) | 2016-01-05 | 2016-01-05 | A kind of drug for treating cough |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456284B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857295A (en) * | 2006-03-22 | 2006-11-08 | 四川国康药业有限公司 | Complex salt or composition medicine of breviscapine and basic amino acid for treating cardiac and cerebral vascular diseases |
-
2016
- 2016-01-05 CN CN201610001603.2A patent/CN105456284B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857295A (en) * | 2006-03-22 | 2006-11-08 | 四川国康药业有限公司 | Complex salt or composition medicine of breviscapine and basic amino acid for treating cardiac and cerebral vascular diseases |
Non-Patent Citations (1)
| Title |
|---|
| 灯盏花素佐治AECOPD的临床效果观察;张秀芬等;《临床合理用药》;20151010;第8卷(第10A期);第35-36页，参见摘要和第3节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105456284A (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| MXPA04010317A (en) | Compositions for preventing or treating pollenosis, allergic nephritis, atopic dermatitits, asthma or urticaria. | |
| CN103212079A (en) | Oral medical composition for preventing and/or treating cold and application thereof | |
| CN104257704B (en) | The new application of Eurycoma longifolia extract product | |
| Frieri | Herbal therapies: what allergist-immunologists should know regarding patient use of complementary and alternative medicine | |
| CN101167937A (en) | Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof | |
| CN100518775C (en) | Medicine composition for treating cough and asthma and preparation thereof | |
| CN100525817C (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| WO2021093090A1 (en) | Traditional chinese medicine extract composition having function of regulating depression, preparation method therefor, and chinese medicine preparation | |
| CN111437338A (en) | Application of traditional Chinese medicine composition in treating skin diseases | |
| CN104523925B (en) | Traditional Chinese medicinal composition and its application in defecation promotion | |
| CN101584810A (en) | Medicine composition for treating gastritis and peptic ulcer and preparation method thereof | |
| CN105456284B (en) | A kind of drug for treating cough | |
| CN102302559B (en) | Medicament for treating respiratory system diseases and application thereof | |
| CN104257795A (en) | Medicine for treating cold | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN110755580B (en) | Traditional Chinese medicine composition with analgesic effect and application thereof | |
| CN111358906B (en) | Traditional Chinese medicine composition suitable for exogenous diseases | |
| Abadian et al. | The biological effects of Teucrium polium on the severity of primary dysmenorrhea | |
| US20040019107A1 (en) | Homeopathic drug composition and methods of use thereof | |
| CN101700373B (en) | Traditional Chinese medicine used for smoking cessation | |
| CN102210827B (en) | Traditional Chinese medicine for stopping smoking | |
| Khatak et al. | A comparative study: Homoeopathic medicine and arnmedicinal plant Withania somnifera for antidiabeticrnactivity | |
| CN107496558B (en) | Composition for treating cough and application thereof | |
| CN101912570B (en) | Medicinal composition for treating rheumatism and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200102 Address after: 432200, No. 1, Chuan long avenue, Huangpi District, Hubei, Wuhan Patentee after: Hubei Chinese Herbal Medicine Co. Address before: No.142, Xingbei Road, Shuangxing village, Shengao Town, Jiangyan City, Taizhou City, Jiangsu Province Patentee before: Li Chunhua |
|
| TR01 | Transfer of patent right |